A Resolution Urging the United States to Decrease Dependence on Pharmaceuticals Manufactured Overseas

Summary

At least 80 percent of the active pharmaceutical ingredients (API) on which Americans rely are manufactured outside the United States – mainly in China. This model policy urges the US Congress to take steps to decrease the nation's dependence on foreign manufactured medicines, particularly from China to ensure the continuity and safety of the supply of the products and keep the American people safe and healthy.

A Resolution Urging the United States to Decrease Dependence on Pharmaceuticals Manufactured Overseas

WHEREAS, many citizens of the United States depend on pharmaceutical drugs to cure, treat, or prevent disease and these drugs can result in lifesaving and life-sustaining outcomes; and

WHEREAS, China has become the world’s largest supplier of active pharmaceutical ingredients (API), and the U.S. Food and Drug Administration estimates that at least 80 percent of active pharmaceutical ingredients are manufactured outside of the United States, mainly in China; and

WHEREAS, China’s dominance in supplying the United States’ chemical and pharmaceutical sector has driven out many U.S. based pharmaceutical companies resulting in a loss of capacity to domestically produce vital drugs used by patients every day; and

WHEREAS, the increased dependence on Chinese produced APIs creates a national security risk that cannot be overstated as it results in U.S. dependence on foreign-sourced pharmaceuticals; and

WHEREAS, in the event of conflict, or as a tool of negotiation, China could weaponize its position in the pharmaceutical supply chain to the disadvantage and peril of the citizens of the United States by manipulating or cutting off the supply of active pharmaceutical ingredients thereby limiting its ability to meet the needs and demands of those Americans dependent on medicines; now, therefore,

BE IT RESOLVED by the legislature in the state of X, that it urges the US Congress to take steps to decrease the nation’s dependence on foreign manufactured medicines, particularly from China to ensure the continuity and safety of the supply of the products and keep the American people safe and healthy; and

BE IT FURTHER RESOLVED that the US Congress develop a White Paper on the methods, materials, and timeline necessary to phase out or reduce American dependence on the manufacture of APIs by potentially hostile powers, such as China and Russia, and that it incentivize the creation or reestablishment of API factories in the United States; and

BE IT FURTHER RESOLVED that copies of this Resolution be transmitted to the President of the United States, the Vice President of the United States, the Speaker of the United States House of Representatives, the Minority Leader of the United States House of Representatives, the President of the United States Senate, the Secretary of Defense, the Secretary of State, the Office of the Surgeon General, the Centers for Disease Control, the US Department of Health and Human Services, the Joint Chiefs Of Staff, Blue Cross Blue Shield Association, Kaiser Permanente, Pfizer, GlaxoSmithKline, Johnson & Johnson, Merck & Co, AbbVie Inc, Bristol-Myers Squibb, Eli Lilly and Company, Biogen, Abbott Laboratories, Stryker Corporation, and Regeneron.